Tobira Therapeutics Inc (TBRA) : Stonepine Capital Management reduced its stake in Tobira Therapeutics Inc by 0.05% during the most recent quarter end. The investment management company now holds a total of 832,977 shares of Tobira Therapeutics Inc which is valued at $6.5 Million after selling 400 shares in Tobira Therapeutics Inc , the firm said in a disclosure report filed with the SEC on May 11, 2016.Tobira Therapeutics Inc makes up approximately 8.15% of Stonepine Capital Management’s portfolio.
Other Hedge Funds, Including , Blackrock Japan Ltd boosted its stake in TBRA in the latest quarter, The investment management firm added 394 additional shares and now holds a total of 1,731 shares of Tobira Therapeutics Inc which is valued at $13,554.Oxford Asset Management reduced its stake in TBRA by selling 20,916 shares or 27.97% in the most recent quarter. The Hedge Fund company now holds 53,871 shares of TBRA which is valued at $421,810. Tobira Therapeutics Inc makes up approx 0.02% of Oxford Asset Management’s portfolio.
Tobira Therapeutics Inc opened for trading at $7.64 and hit $8.365 on the upside on Monday, eventually ending the session at $8.29, with a gain of 5.87% or 0.46 points. The heightened volatility saw the trading volume jump to 30,063 shares. Company has a market cap of $156 M.
Many Wall Street Analysts have commented on Tobira Therapeutics Inc. H.C. Wainwright Initiated Tobira Therapeutics Inc on Apr 11, 2016 to “Buy”, Price Target of the shares are set at $22.
Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.